Post by
SPCEO1 on Nov 29, 2021 11:52am
I try to remind myself
That every day that goes by without news increases the chances of some preliminary efficacy and PoC being seen.
But the long wait for data is always hard for biotech investors.
I would think we are very close to hearing the trial has ended due to more SAE's in the additional patients recruited at the 2x normal Docetaxel dose level or we will be waiting until January as they did not have any trial-halting SAE's at the 2x level and are now moving to the 3x level. While the former would not be a bad outcome in my view, the latter would be better since the more Docetaxel you can get into the body safely, the better the chances of killing off cancer cells.
Comment by
longterm56 on Nov 29, 2021 1:46pm
I need more of that "reminding". Good thing the Phase 1a is "an open trial", or we might not know what is really going on! lol -LT
Comment by
Bucknelly21 on Nov 29, 2021 3:13pm
Almost back under the $300 million market cap congratulations to Thtx and their IR teams wonderful strategy to engage the market and tackle the "ridiculous" share price
Comment by
retiredRIA on Nov 29, 2021 3:53pm
I guess I am the only one taking advantage of this Black Monday sale of THTX!
Comment by
SPCEO1 on Nov 29, 2021 4:04pm
Another factor leading to selling today could be someone facing an imminent margin call and selling TH to try to get ahead of that following Friday's market meltdown.